1.The clinical study of the tuberculous spondylitis.
Byung Jik KIM ; han Suk KO ; Young LIM ; Jung Gook SEO ; Suk Kyu ZOO ; Tae Hwan JEON
The Journal of the Korean Orthopaedic Association 1993;28(6):2221-2232
No abstract available.
Spondylitis*
2.Efficacy and Safety of "Tension-free" Placement of Gynemesh PS for the Treatment of Anterior Vaginal Wall Prolapse.
Young Suk LEE ; Deok Hyun HAN ; Soo Hyun LIM ; Tae Heon KIM ; Myung Soo CHOO ; Ju Tae SEO ; Jeong Zoo LEE ; Byung Soo CHUNG ; Jeong Gu LEE ; Kyu Sung LEE
International Neurourology Journal 2010;14(1):34-42
PURPOSE: To evaluate the efficacy and safety of the tension-free placement of a monofilament polypropylene mesh for the repair of an anterior vaginal wall prolapse (AVWP). MATERIALS AND METHODS: Women aged > or = 30 years with an AVWP stage of II or greater were included. Forty-nine women underwent trans-vaginal repair using a Gynemesh(TM) PS. Forty-six women who had symptomatic stress urinary incontinence received a midurethral sling (MUS). At the 12-month follow-up, evaluations were made for changes in the Pelvic Organ Prolapse Quantification (POP-Q) stage and Pelvic Floor Distress Inventory. Cure was defined as a POP-Q stage of 0 and improvement as a stage of I. Complications were also evaluated. RESULTS: The cure rate was 71.4%, and the improvement rate was 18.4%. Obstructive/discomfort, irritative, and stress subscale scores of the Urinary Distress Inventory anterior and posterior subscale scores of the POP Distress Inventory and the obstructive subscale score of the Colo-Rectal-Anal Distress Inventory were significantly improved. Thirty-two of the 46 women (69.6%) who received MUS procedures reported no leakage after surgery. Complications were 2 cases of increased intraoperative bleeding and 1 case of vaginal erosion. CONCLUSIONS: Trans-vaginal repair using a Gynemesh(TM) PS is a feasible and effective procedure for the treatment of AVWP with no significant complications.
Aged
;
Animals
;
Female
;
Follow-Up Studies
;
Hemorrhage
;
Humans
;
Lower Urinary Tract Symptoms
;
Mice
;
Pelvic Floor
;
Pelvic Organ Prolapse
;
Polypropylenes
;
Prolapse
;
Suburethral Slings
;
Urinary Incontinence
3.Efficacy of an Alpha-Blocker for the Treatment of Nonneurogenic Voiding Dysfunction in Women: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Young Suk LEE ; Kyu Sung LEE ; Myung Soo CHOO ; Joon Chul KIM ; Jeong Gu LEE ; Ju Tae SEO ; Jeong Zoo LEE ; Ji Youl LEE ; Seung June OH ; Yong Gil NA
International Neurourology Journal 2018;22(1):30-40
PURPOSE: To evaluate the efficacy of an alpha-1 adrenergic receptor (α1-AR) blocker for the treatment of female voiding dysfunction (FVD) through a pressure-flow study. METHODS: This was a randomized, double-blind, placebo-controlled trial. Women aged ≥18 years with voiding symptoms, as defined by an American Urological Association symptom score (AUA-SS) ≥15 and a maximum flow rate (Qmax) < 15 mL/sec with a voided volume of >100 mL and/or a postvoid residual (PVR) volume >150 mL, were randomly allocated to either the alfuzosin or placebo group. After 8 weeks of treatment, changes in the AUA-SS, Bristol female lower urinary tract symptoms (BFLUTS) questionnaire, Qmax/PVR, and voiding diary were compared between groups. Patients’ satisfaction with the treatment was compared. Patients were categorized into 3 groups according to the Blaivas-Groutz bladder outlet obstruction (BOO) nomogram: none, mild, and moderate to severe. Subgroup comparisons were also made. RESULTS: Of a total of 187 women, 154 (79 alfuzosin, 75 placebo) were included in the analysis. After 8 weeks of treatment, the AUA-SS decreased by 7.0 in the alfuzosin group and by 8.0 in the placebo group. Changes in AUA-SS subscores, BFLUTS (except the I-sum), the voiding diary, and Qmax/PVR were not significantly different between groups. Approximately 54% of the alfuzosin group and 62% of the placebo group were satisfied with the treatment. No significant difference was observed between groups according to the presence or grade of BOO. CONCLUSIONS: Alfuzosin might not be more effective than placebo for treating FVD. The presence or the grade of BOO did not affect the results. A further study with sufficient power is needed to determine the efficacy of α1-AR blockers for the treatment of FVD.
Adrenergic alpha-Antagonists
;
Female
;
Humans
;
Lower Urinary Tract Symptoms
;
Nomograms
;
Receptors, Adrenergic, alpha-1
;
Urinary Bladder Neck Obstruction
;
Urodynamics